Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
Titel:
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
Auteur:
Pabst, Thomas Papayannidis, Cristina Demirkan, Fatih Doronin, Vadim Fogliatto, Laura M Guttke, Christina Gyan, Emmanuel Hamad, Nada Herrera, Pilar Hultberg, Anna Jacobs, Julie Johnson, Amy J Langlois, Angélique Ma, Xuewen Martinelli, Giovanni Arnan, Montserrat Müller, Rouven Nottage, Kerri Ofran, Yishai Özcan, Muhit Samoilova, Olga Tolbert, Jaszianne A Trudel, Géralyn C Xiu, Liang Vey, Norbert Wei, Andrew H